A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin

Jeremy T. LarsenDepartment of Medicine

William J. HoganDivision of Hematology, Department of Medicine

Ivana N. MicallefDivision of Hematology, Department of Medicine

Angela DispenzieriDivision of Hematology, Department of Medicine

Morie A. GertzDivision of Hematology, Department of Medicine

David J. InwardsDivision of Hematology, Department of Medicine

Han W. TunHematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, USA

Vivek RoyHematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, USA

Susan M. GeyerHematology, Ohio State University, Columbus, OH, USA

Jacob B. AllredBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

Wenting WuBiomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

Stephen M. AnsellDivision of Hematology, Department of Medicine

Michelle A. ElliottDivision of Hematology, Department of Medicine

Ayalew TefferiDivision of Hematology, Department of Medicine

Luis F. PorrataDivision of Hematology, Department of Medicine

Dennis A. GastineauDivision of Hematology, Department of Medicine

Martha Q. LacyDivision of Hematology, Department of Medicine

Mark R. LitzowDivision of Hematology, Department of MedicineCorrespondence[email protected]

Your download is now in progress and you may close this window